Biotechnology

JW THERAP-B

JW THERAP-B released FY2025 Q3 earnings on March 26 (BJT), actual revenue HKD 96.91 M, actual EPS HKD -0.3784

JW THERAP-B released FY2025 9-month earnings on March 26 (BJT), actual revenue HKD 212.06 M, actual EPS HKD -1.0747

JW THERAP-B released FY2025 Q4 earnings on March 26 After-Market (BJT), actual revenue HKD 98.59 M, actual EPS HKD -0.3876

JW THERAP-B released FY2025 earnings on March 26 After-Market BJT, actual revenue HKD 310.02 M (forecast HKD 271.34 M), actual EPS HKD -1.4596 (forecast HKD -1.1453)

JW THERAP-B to Release FY2025 Annual Earnings on March 26 After-Market (BJT), Forecast Revenue HKD 266.92 M, EPS HKD -1.1267

JWCTAR201 IIT Research Data Released by Juno Therapeutics-B

5 CAR-T Cell Therapy Products Included in the First Batch of Commercial Insurance Innovative Drug Catalog

Yumeng Juno's CAR-T Cell Drug Aims for Inclusion in Commercial Insurance Innovative Drug Catalog

JW Therapeutics Submits First-in-Human Phase I Data for Relmacabtagene Autoleucel

JW Therapeutics' Relmacabtagene Ablamelical (Relma-Cel) Supplemental Application for Domestic Slow Virus Vector Approved for Filing by NMPA

CICC Raises JUNO Therapeutics' Target Price to HKD 6.04

JW THERAP-B released FY2025 Q1 earnings on August 27, 2025 (BJT) with actual revenue of HKD 56.95 M and EPS of HKD -0.3427

JW THERAP-B released FY2025 Semi-Annual Earnings on August 27 After-Market (BJT), actual revenue HKD 115.15 M, actual EPS HKD -0.6962

JW THERAP-B released FY2025 Q2 earnings on August 27 After-Market (BJT), actual revenue HKD 58.2 M, actual EPS HKD -0.3519

JW THERAP-B to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

JW Therapeutics Stock Doubles, CAR-T Product Approved in Macau

JW Therapeutics Stock Rises, New Drug Approved in Macau

JW Therapeutics’ CAR-T Product Approved for Market in Macau

JW Therapeutics' New Drug Approved in Macau, Stock Price Rises

JW Therapeutics Announces Acceptance of New IND Application for Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

603259

02359

XPEV

09868

02126

01299

Morgan Stanley released a global thematic investment report, emphasizing the importance of thematic research, believing it can identify attractive investment opportunities amid market volatility. The four core themes for 2026 are technology diffusion, the future of energy, a multipolar world, and social transformation. The thematic investment stock list for the Asia-Pacific region includes AIA, Tencent, WuXi AppTec, XPeng, and others

AASTOCKS

WuXi AppTec

WUXI APPTEC

XPeng

XPENG-W

Morgan Stanley lists thematic investment stock list for the Asia-Pacific region (including Japanese stocks) (table)

JW Therapeutics has announced key leadership changes, appointing Mr. Tian Feng as the new CEO and Executive Director, effective December 29, 2025. Mr. Tian has over 20 years of experience in the biopharmaceutical industry. These changes aim to enhance the company's strategic direction and operational efficiency. The stock is currently rated as Hold with a HK$3.00 price target.

Tip Ranks

JW Therapeutics Announces Key Leadership Changes

JW Therapeutics announced its board composition, detailing roles and functions of non-executive and independent directors. Members serve on committees like Audit, Remuneration, Nomination, and Business Development and Strategy. This governance structure impacts the company's strategic direction. Analyst rating for JW stock (HK:2126) is Hold with a HK$3.00 target. JW Therapeutics focuses on innovative cell-based therapies in healthcare.

JW Therapeutics Announces Board Composition and Roles

JW THERAP-B (2126.HK) faced continued market pressure yesterday, with a short-term structure showing signs of overselling and bottom-seeking. The trading volume hit a new low for the day, with funds continuously flowing out and active buying being constrained. Technical bearish signals were significantly amplified, and fund rotation within the sector was slow, with right-side funds closely monitoring key support levels below. This week, the pharmaceutical sector as a whole is facing regulatory and policy pressures, leading to a sharp decline in market risk appetite. With frequent news on volume-based procurement, the bargaining power of innovative drug companies is once again under pressure, and pharmaceutical-themed funds are maintaining low positions, creating a strong wait-and-see atmosphere. JW THERAP-B has seen no industry positives for three days, with main funds leaning towards defensive strategies, and any intraday rebounds were quickly interrupted by selling pressure. Traders are focusing on the defensive role and the potential recovery window for sector rotation; if external sentiment warms up, a technical rebound may occur. The potential risks of short-term market fluctuations cannot be ignored, and dynamic position management and monitoring of volume signals are the main operational disciplines

Technical Forecast

Morning Trend | JW THERAP-B Oversold Seeking Bottom, Where is the Sector Rotation Window Under Pharmaceutical Divergence?

JW THERAP-B rose over 10%, as of the time of writing, it increased by 9.77%, priced at HKD 3.82, with a transaction volume of HKD 4.6331 million. According to a report by Yicai, on November 2, it was learned that JW THERAP's CAR-T cell drug, Rukiyolunase injection, is making smooth progress in negotiations to enter the commercial health insurance innovative drug catalog, with hopes of being included in the catalog, reducing the medication burden for patients and benefiting more patients. This is the first domestically approved Class 1 CAR-T in China, with a post-listing price of 1.29 million yuan per injection. On October 30, JW THERAP announced the signing of a strategic cooperation supplementary agreement with Regeneron Pharmaceuticals. This revision not only marks an important upgrade in the long-term cooperative relationship between the two parties but also opens a new phase of collaboration in TCR-T cell therapy and platform technology innovation. Through this supplementary agreement, JW THERAP will receive payments of up to USD 50 million, including milestone payments for MAGE-A4 product development, drug production process supervision milestone payments, option exercise fees, and milestone payments for lentiviral vector manufacturing processes

Zhitong

Understanding the Market | JW THERAP-B rose over 10% as reports suggest its CAR-T drug is expected to enter the commercial insurance catalog

02575

01228

03681

百奥赛图-B

08622

On October 27th, the Hong Kong stock market saw significant gains in the pharmaceuticals and biotechnology sector. XUANZHUBIO-B rose nearly 19%, CANBRIDGE-B increased over 14%, SINOMAB BIO-B climbed over 11%, BAIOO SAI TU-B and HUAKANG BIOMED both surged over 9%, and JW THERAP-B rose over 8%

XUANZHUBIO-B

CANBRIDGE-B

SINOMAB BIO-B

JOYZYME GROUP

The Hong Kong stock market's pharmaceutical and biotechnology sector leads in gains